Comparative Analysis of Heart Rate Variability in Patients with Cervical Pain, Lumbar Pain, and Healthy Controls

March 23, 2025 updated by: Carlos Fernández-Morales, Universidad de Extremadura
This is a cross-sectional study designed to evaluate potential differences in heart rate variability (HRV) indices based on the affected body region (cervical vs lumbar) in individuals with chronic pain. The study will compare HRV parameters between three groups: individuals with chronic neck pain (CNP), individuals with chronic low back pain (CLBP), and a control group without pain. HRV will be assessed using a Firstbeat Bodyguard® device over a 10-minute period, and the data will be analyzed with Kubios® HRV software. The study aims to determine whether autonomic nervous system modulation differs depending on the location of chronic pain.

Study Overview

Study Type

Observational

Enrollment (Actual)

93

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Badajoz, Spain, 06006
        • Universidad de Extremadura

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study will include three groups: one group of adults diagnosed with chronic neck pain (CNP), one group of adults diagnosed with chronic low back pain (CLBP), and another group of healthy adults within the same age range. Participants will be recruited from local community advertisements and hospital outpatient clinics.

Description

Inclusion Criteria:

  • - Adults aged between 18 and 65 years.

For the chronic low back pain group:

  • Diagnosis of chronic neck or low back pain lasting at least three months.
  • A minimum pain intensity of 3/10 on the Numerical Pain Rating Scale (NPRS).

For the healthy group:

  • Absence of any chronic or acute pathology.
  • No regular medication that could alter autonomic nervous system function.
  • No episodes of low back pain in the past six months.

Exclusion Criteria:

  • Presence of uncontrolled neurological or cardiac disorders.
  • Use of medications that could influence autonomic function or pain perception (e.g., opioids, antidepressants, benzodiazepines, anti-inflammatory drugs, beta-blockers) within two weeks prior to the study.
  • Body Mass Index (BMI) equal to or greater than 30 kg/m².

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Healthy Subjects
This group includes adults aged 18-65 years without any chronic or acute pathology, no regular medication that could alter autonomic nervous system function, and no low back pain in the past six months.
Chronic Low Back Pain Subjects
This group includes adults aged 18-65 years diagnosed with chronic low back pain lasting at least three months, with a minimum pain intensity of 3/10 on the Numerical Pain Rating Scale, and without uncontrolled neurological or cardiac disorders.
Chronic Neck Pain Subjects
This group includes adults aged 18-65 years diagnosed with chronic neck pain lasting at least three months, with a minimum pain intensity of 3/10 on the Numerical Pain Rating Scale, and without uncontrolled neurological or cardiac disorders.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Root Mean Square of Successive Differences (rMSSD)
Time Frame: Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
This variable represents a time-domain measure of heart rate variability, reflecting parasympathetic nervous system activity and short-term variability in R-R intervals. It is calculated as the root mean square of differences between successive R-R intervals. rMSSD is an established metric to assess vagal modulation and is sensitive to changes in autonomic function.
Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
Stress Score (SS)
Time Frame: Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
This variable is calculated as the reciprocal of SD2, multiplied by 1000. It reflects the level of sympathetic activation, where higher Stress Score values indicate increased stress and reduced parasympathetic activity.
Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
Sympathetic/Parasympathetic Ratio (S/PS Ratio)
Time Frame: Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
This variable represents the ratio of Stress Score to SD1. It reflects the balance between sympathetic and parasympathetic modulation, with higher values indicating sympathetic dominance, commonly observed in chronic pain conditions.
Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
Standard Deviation 1 (SD1)
Time Frame: Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
A non-linear metric derived from the Poincaré plot of heart rate variability, indicating short-term variability in R-R intervals. It is closely associated with parasympathetic activity and vagal modulation.
Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
Standard Deviation 2 (SD2)
Time Frame: Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
A non-linear metric derived from the Poincaré plot, representing long-term variability in R-R intervals. SD2 is inversely related to sympathetic activity and reflects the balance between sympathetic and parasympathetic modulation.
Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Heart Rate (Mean HR)
Time Frame: Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
Represents the average heart rate (beats per minute) recorded during the data collection period. It serves as a general indicator of autonomic activity, providing insights into the balance between sympathetic and parasympathetic modulation.
Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
Maximum Heart Rate (Max HR)
Time Frame: Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
Represents the highest heart rate (beats per minute) recorded during the data collection period. This variable reflects periods of sympathetic activation and provides insights into stress responses during the session.
Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
Minimum Heart Rate (Min HR)
Time Frame: Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.
Represents the lowest heart rate (beats per minute) recorded during the data collection period. This variable reflects periods of parasympathetic predominance and is useful for assessing vagal.
Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Luis Espejo-Antúnez, Ph.D., University of Extremadura

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 15, 2020

Primary Completion (Actual)

December 11, 2022

Study Completion (Actual)

December 11, 2022

Study Registration Dates

First Submitted

March 17, 2025

First Submitted That Met QC Criteria

March 17, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 26, 2025

Last Update Submitted That Met QC Criteria

March 23, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 09

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Neck Pain

Subscribe